MTAP and mesothelioma: In agreement with previous studies underlining the potential value of PRMT5 as a therapeutic approach,58, 59, 60, 61 our results represent a starting point for the evaluation of PRMT5 inhibitors also in MTAP‐deleted mesothelioma.